UNIVERSAL HEPATITIS C VIRUS SCREENING IN A TENNESSEE TERTIARY CARE EMERGENCY DEPARTMENT

Cody A. Chastain^{1,} Jakea Johnson², Karen Miller², Katie Moore², Amanda Lako², Autumn Zuckerman³, Jin Han², Wesley H. Self²

Department of Medicine¹
Department of Emergency Medicine²
Vanderbilt Specialty Pharmacy³
Vanderbilt University Medical Center



DISCLOSURES

- Chastain: Research/grant support from Gilead Sciences, Inc.
- Self: Research/grant support from Gilead Sciences, Inc.



BACKGROUND


- HCV screening guidelines include risk factor and age cohort recommendations
- Prior ED screening programs have identified high rates of HCV prevalence
 - 13.8% antibody (Ab) positive among baby boomers in Baltimore, MD
 - 11.1% Ab positive among baby boomers in Birmingham, AL
 - 13.9% Ab positive in Cincinnati, OH
 - 13.2% Ab positive in Boston, MA
- Universal, opt-out programs successfully implemented in other ED programs
- Evolving opioid epidemic across US and notably in Appalachia related to HCV



METHODS

- Universal screening in tertiary care center emergency department
- All patients age 18 or older who had blood obtained for clinical care eligible for opt-out testing
- Patients age <18, without phlebotomy as part of clinical care, and/or inability to participate in opt-out testing excluded from initiative






RESULTS

- Program roll out 12/2016 with evolution to standard protocol by start of report period
- Report period 4/1/17 3/31/18 (12 month)
- 11,637 screening tests performed
 - 1,008 (8.7%) HCV Ab positive
 - 488 (4.2%) HCV RNA positive
 - 81 (0.7%) HCV Ab positive, RNA unknown
 - Some samples with inadequate volume for reflex RNA testing
- NOTE: Some data missing for individual entries (i.e. gender, age, risk factors, etc.). Data reported reflects known populations.

Advancing Science, Improving Ca



RESULTS CONT.

Table 2: Demographics Among HCV RNA + (n=488)

<u>Demographics</u>	<u>N (%)</u>
People Born 1945-1965	178 (36.5%)
People Not Born 1945-1965	310 (63.5%)
Women Age 18-45	77 (15.8%)
Reported / Known Injection Drug Use	154 (31.6%)
People Not Born 1945-1965 With No Known Injection Drug Use	179 (36.7%)

DISCUSSION

- Universal emergency department screening produced high yield of HCV Ab + tests
 - 8.7% Ab positive
- Presumed spontaneous clearance rate of HCV higher than in historical reports and more consistent with more recent literature
 - 4.2% RNA positive
 - 0.7% with indefinite HCV RNA status
- While rate of HCV in non-baby boomers lower, rate detected in non-baby boomer emergency department patients relatively high and represented the majority of positive tests
 - 7.2% Ab positive
 - 3.9% RNA positive
- Women 18-45 had clinically relevant rates of HCV
 - 5.9% Ab positive
 - 2.9% RNA positive
- Relying on age cohort screening and known injection drug use status would have missed >1/3 of HCV RNA positive individuals

Advancing Science, Improving Care

36.7% of all HCV RNA positive cases

DISCUSSION CONT.

Conclusions

- Universal HCV screening in a Tennessee tertiary care emergency department identified a high rate and volume of HCV + individuals, though less than noted in other urban settings
- Screening in emergency departments may yield outcomes that differ from general population or outpatient clinic screening
- Screening in emergency departments may assist in identifying certain at-risk groups that may not be screened in other settings
- Optimal screening criteria in non-traditional settings may differ from historic, guideline-recommended criteria
- Spontaneous clearance rate in population diagnosed in emergency department is likely higher than reported in historical estimates

Future Directions

- Further study underway regarding reason for presentation to ED, additional characteristics that can maximize yield from more focused screening
- Additional study of linkage to care and impact of screening program on outcomes ongoing to optimize best practice



ACKNOWLEDGMENTS AND THANKS

- Supported in part by grant funding through the Frontlines of Communities in the United States (FOCUS) Program, Gilead Sciences, Inc.
- Vanderbilt ED Clinical and Research Personnel
- Patient Participants

